S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:CDNACareDx Stock Price, Forecast & News

$32.46
-0.51 (-1.55 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$32.24
Now: $32.46
$33.36
50-Day Range
$30.91
MA: $33.74
$35.95
52-Week Range
$13.04
Now: $32.46
$37.54
Volume304,895 shs
Average Volume710,501 shs
Market Capitalization$1.59 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.01
CareDx, Inc., a precision medicine company, discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a solution for use in transplantation diagnostic testing. Further, the company provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI and Waitlist Management solutions. It offers its products directly to customers, as well as through third-party distributors. The company has a license agreement with Illumina, Inc. for the development, commercialization, and distribution of next generation sequencing product line for use in transplantation diagnostic testing; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Read More
CareDx logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.6Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.56 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDNA
CUSIPN/A
Phone415-287-2300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$127.07 million
Book Value$5.33 per share

Profitability

Net Income$-21,970,000.00

Miscellaneous

Employees306
Market Cap$1.59 billion
Next Earnings Date10/29/2020 (Estimated)
OptionableOptionable
$32.46
-0.51 (-1.55 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for CDNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CareDx (NASDAQ:CDNA) Frequently Asked Questions

How has CareDx's stock price been impacted by Coronavirus?

CareDx's stock was trading at $18.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CDNA stock has increased by 71.4% and is now trading at $32.46.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of CareDx?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CareDx
.

When is CareDx's next earnings date?

CareDx is scheduled to release its next quarterly earnings announcement on Thursday, October 29th 2020.
View our earnings forecast for CareDx
.

How were CareDx's earnings last quarter?

CareDx Inc (NASDAQ:CDNA) announced its quarterly earnings data on Tuesday, August, 4th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.08. The firm had revenue of $41.80 million for the quarter, compared to analyst estimates of $35.61 million. CareDx had a negative net margin of 12.66% and a negative return on equity of 13.58%. The business's revenue for the quarter was up 32.9% on a year-over-year basis.
View CareDx's earnings history
.

What price target have analysts set for CDNA?

7 analysts have issued 12-month price objectives for CareDx's stock. Their forecasts range from $35.00 to $63.00. On average, they anticipate CareDx's share price to reach $45.86 in the next twelve months. This suggests a possible upside of 41.3% from the stock's current price.
View analysts' price targets for CareDx
.

Has CareDx been receiving favorable news coverage?

Media headlines about CDNA stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CareDx earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about CareDx
.

Are investors shorting CareDx?

CareDx saw a increase in short interest during the month of May. As of May 29th, there was short interest totaling 5,590,000 shares, an increase of 12.5% from the May 14th total of 4,970,000 shares. Based on an average trading volume of 707,400 shares, the days-to-cover ratio is presently 7.9 days.
View CareDx's Short Interest
.

Who are some of CareDx's key competitors?

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Roku (ROKU), Square (SQ), EXACT Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Johnson & Johnson (JNJ), Netflix (NFLX), Alibaba Group (BABA) and Aduro BioTech (ADRO).

Who are CareDx's key executives?

CareDx's management team includes the following people:
  • Dr. Peter Maag, Chairman & CEO (Age 53, Pay $1.08M)
  • Dr. Reginald Seeto, Pres & Chief Bus. Officer (Age 48, Pay $826k)
  • Mr. Michael Bell, Chief Financial Officer (Age 51, Pay $686.59k)
  • Ms. Sasha King M.B.A., Chief Marketing Officer (Age 34, Pay $509.2k)

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

Who are CareDx's major shareholders?

CareDx's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.92%), Bellevue Group AG (2.38%), Gagnon Securities LLC (2.21%), Granite Investment Partners LLC (1.76%), Bamco Inc. NY (1.58%) and Sumitomo Mitsui Trust Holdings Inc. (1.61%). Company insiders that own CareDx stock include James P Yee, Michael Brian Bell, Michael Goldberg, Neil Gagnon, Peter Maag, Sasha King and William A Hagstrom.
View institutional ownership trends for CareDx
.

Which major investors are selling CareDx stock?

CDNA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Redwood Investments LLC, Balyasny Asset Management LLC, Bellevue Group AG, Gagnon Advisors LLC, PDT Partners LLC, Gagnon Securities LLC, and Ziegler Capital Management LLC. Company insiders that have sold CareDx company stock in the last year include Michael Brian Bell, Michael Goldberg, Peter Maag, Sasha King, and William A Hagstrom.
View insider buying and selling activity for CareDx
.

Which major investors are buying CareDx stock?

CDNA stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Nordea Investment Management AB, Bamco Inc. NY, Vanguard Group Inc., William Blair Investment Management LLC, Zweig DiMenna Associates LLC, and Monashee Investment Management LLC.
View insider buying and selling activity for CareDx
.

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $32.46.

How big of a company is CareDx?

CareDx has a market capitalization of $1.59 billion and generates $127.07 million in revenue each year. The company earns $-21,970,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. CareDx employs 306 workers across the globe.

What is CareDx's official website?

The official website for CareDx is www.caredxinc.com.

How can I contact CareDx?

CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-287-2300 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.